Current Edition

Biosimilars: Experience to Date and the Potential to Improve Access in the United States

Currently, the global biosimilars market includes monoclonal antibody (mAb) biosimilars for the treatment of cancer and autoimmune conditions (e.g., rheumatoid arthritis), as well as insulin’s, interferons, erythropoietin, filgrastim, somatropin and follicle stimulating hormone. Nigel Rulewski, Raymond A. Huml, Tracy Stewart and Deepa Dahal of Quintiles discuss the development of the emerging field that is generating high levels of interest within industry, and offers the prospect of increasing patient access to highly effective medicines.